☆ 4.5 Article

Stereotactic body radiation therapy for prostate cancer: a study comparing 3-year genitourinary toxicity between CyberKnife and volumetric-modulated arc therapy by propensity score analysis

RADIATION ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer The MIRAGE Randomized Clinical Trial

Amar U. Kishan et al.

Summary: MRI-guided SBRT significantly reduces acute grade 2 or greater GU toxic effects and GI toxic effects compared to CT-guided SBRT. This randomized clinical trial provides evidence for the benefits of MRI guidance in prostate cancer treatment. Further follow-up is needed to confirm the long-term effects.

JAMA ONCOLOGY (2023)

Add to Collection

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Biology

SBRT for Localized Prostate Cancer: CyberKnife vs. VMAT-FFF, a Dosimetric Study

Marcello Serra et al.

Summary: Stereotactic body radiation therapy (SBRT) has become a popular method for treating medium and low risk prostate cancer. It offers high doses of radiation in a small number of fractions, taking advantage of the prostate's different radiosensitivity compared to healthy tissues. SBRT treatment has been shown to provide a better quality of life compared to surgery. The study compared two SBRT techniques, CyberKnife (CK) and Volumetric Modulated Arc Therapy (VMAT), and found that while CK had better dose delivery, VMAT-FFF offered shorter delivery time and showed promise as an alternative SBRT technique for localized prostate cancer.

LIFE-BASEL (2022)

Add to Collection

Article Oncology

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison C. Tree et al.

Summary: The PACE-B trial showed that 2-year toxicity rates were similar for five fraction SBRT and conventional schedules of radiotherapy in the treatment of localized prostate cancer. SBRT was found to be safe and associated with low rates of side effects. The study highlights the potential of SBRT as an effective treatment option for prostate cancer.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response

Kyle Wang et al.

Summary: Multiple studies have shown that prostate SBRT therapy is well tolerated overall with mainly mild to moderate toxicities and very low incidence of severe toxicities. Side effects are influenced by both dosimetric and non-dosimetric factors. Further research is needed to explore tolerance doses in the future.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Article Oncology

Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines

Edward Schaeffer et al.

Summary: The NCCN Guidelines for Prostate Cancer provide recommendations for staging and risk assessment post-diagnosis, with management options for localized, regional, and metastatic disease. The guidelines also cover disease monitoring and treatment of recurrent disease. The NCCN Prostate Cancer Panel meets annually to update recommendations based on new clinical data, aiming to provide the most effective care for patients.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer

Makoto Ito et al.

Summary: After comparing five radiotherapy methods for prostate cancer, it was found that high-dose-rate brachytherapy performed better in terms of genitourinary toxicities, while ultra-hypofractionated radiotherapy showed inferior results in this aspect. In addition, a higher symptom score peak was noted after low-dose-rate brachytherapy treatment.

ANTICANCER RESEARCH (2021)

Add to Collection

Article Oncology

Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities

Makoto Ito et al.

Summary: This study reported the 2-year results of stereotactic body radiation therapy for prostate cancer and identified clinical and dosimetric factors predicting acute genitourinary toxicities. The findings suggest that stereotactic body radiation therapy is feasible for Japanese patients with prostate cancer and is associated with acceptable acute toxicity. Age, genitourinary toxicity at baseline, and bladder mean dose were identified as predictors of grade 2 acute genitourinary toxicity.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials

Marco Marcello et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

Anders Widmark et al.

LANCET (2019)

Add to Collection

Article Oncology

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas H. Brand et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma

Sergiu Scobioala et al.

RADIATION ONCOLOGY (2019)

Add to Collection

Article Oncology

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

Himanshu R. Lukka et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)

Add to Collection

Article Oncology

Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial

Kyle Wang et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Is it essential to use fiducial markers during cone-beam CT-based radiotherapy for prostate cancer patients?

Berna A. Yildirim et al.

JAPANESE JOURNAL OF RADIOLOGY (2017)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Is it essential to use fiducial markers during cone-beam CT-based radiotherapy for prostate cancer patients?

Berna A. Yildirim et al.

JAPANESE JOURNAL OF RADIOLOGY (2017)

Add to Collection

Article Oncology

Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer

Li Zhang et al.

PRACTICAL RADIATION ONCOLOGY (2017)

Add to Collection

Article Oncology

Use, Complications, and Costs of Stereotactic Body Radiotherapy for Localized Prostate Cancer

Joshua A. Halpern et al.

CANCER (2016)

Add to Collection

Article Biophysics

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

Y. Kanda

BONE MARROW TRANSPLANTATION (2013)

Add to Collection

Article Oncology

Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study

Filippo Alongi et al.

RADIATION ONCOLOGY (2013)

Add to Collection

Article Oncology

Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy

Jeffrey Vainshtein et al.

RADIATION ONCOLOGY (2012)

Add to Collection

Article Oncology

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference

Mack Roach et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.